Interestingly, within BRAF V600E/K mutated MM tumors, the number of TIL clusters was associated with improved survival (median overall survival rate BRAF V600E/K with low clusters: 48.2 vs. BRAF V600E/K with high clusters: 86.9 months, p < 0.0001, n = 164; Fig. 3) but this effect was not seen in neither NRAS-mutated MM patients, (55.7 months vs. 63.0 months, respectively, p = 0.590, n = 85) nor wildtype MM patients (52.4 months vs. 47.4 months, respectively, p = 0.581, n = 104). The gene discussed is NRAS; the disease is Miyoshi myopathy.